Called the Innovator Community Expansion Initiative, the main goal of the effort is to pinpoint and remove obstacles keeping underrepresented groups, like women, out of the innovation process. The initiative will promote networking and education about the path to commercialization.
The hedge fund administrator SS&C Technologies Holdings will be the majority stakeholder, while the two payers will each hold a minority interest in the joint venture, dubbed DomaniRx. The company will develop a claims adjudication platform to support its operations.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The health technology company offers a platform that enables clinicians to more quickly and accurately complete specialty drug enrollment processes. The goal is to simplify the administrative burden on providers and get patients quicker access to the medications they need.
PBMs who are transparent, offer formularies that reduce wasteful spending and have experience in specialty pharmacy are better poised to meet the needs of plan sponsors and ensure the most affordable drug coverage options.
The Department of Justice sued Omnicare for allegedly dispensing drugs without valid prescriptions.
Through the Splunk controlled substance monitoring platform, NewYork-Presbyterian can see if medications are being diverted for potentially illegitimate purposes, like a doctor prescribing a medication to a patient not currently in the hospital.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company's Individual Risk Identification Score, or IRIS, uses machine learning to help hospitals pinpoint employees who pose a high risk for drug diversion.
These numbers compare to 2017, when 20.9 million pills and $301.1 million were lost because of drug diversion, according to an analysis by data analytics company Protenus.
Determined to explore more avenues to curb price hikes, the Trump administration is signaling that it is willing to consider what the industry regards as something of a nuclear option to address a recalcitrant problem.
President Donald Trump has railed against the high price of prescription drugs, yet many Americans aren’t seeing a change in what they pay out-of-pocket. Here’s a look at the rhetoric thus far versus the results.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The acquisition not only reflects the interest in connecting insurance companies to PBMs but it also raises questions about what it could mean for drug prices in the future.
In a recent phone interview, pharmacist Michael Rea explained why he founded Rx Savings Solutions, its goals for the year ahead and its $18.4 million funding round led by McCarthy Capital.
The final draft of the National Defense Authorization Act would give the Pentagon authority to decide when unapproved drugs and devices, referred to as agents of war in the legislation, could be used on military personnel in an emergency. This proposal is a bad idea and should be dropped.
Investing in a smart, tailored real-world evidence plan from the beginning of drug development may seem expensive and premature, but it can lead to significant cost savings.
Well-designed real-world evidence studies have gained acceptance by regulators and payers, who once viewed them with skepticism. Here is what you need to consider.